Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 2/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015205 | 0.86 | KIF11 (0.33) | KIF11 | |
| SCHEMBL5015183 | 0.82 | FABP4 (0.38) | — | |
| SCHEMBL1792650 | 0.77 | RXRA (0.32) | KIF11 | |
| SCHEMBL5013913 | 0.76 | — | — | |
| SCHEMBL5015198 | 0.76 | MAPT (0.38) | CLK1CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5015257 | 0.71 | CYP1A1 (0.39) | SMN1; SMN2 | |
| SCHEMBL14657716 | 0.70 | — | — | |
| SCHEMBL5013036 | 0.70 | RAPGEF4 (0.30) | — | |
| SCHEMBL5016486 | 0.70 | TOP1 (0.35) | SMN1; SMN2 | |
| SCHEMBL5011952 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417142-B2 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-09 | — | — | US | disclosed |
| US-20050124596-A1 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | PPOX, HCCS, ICOSLG | KIF11 3643/4885ENPP1 2729/4885BACE1 4333/4885 |
| US-20050124596-A1 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | PPOX, PPIF, HMBS | KIF11 4298/4885ENPP1 504/4885BACE1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.